A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia
Clinical trial NCT02733042 · COMPLETED
Trial details
- NCT number
- NCT02733042
- Sponsor
- Celgene
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-05-11
- Primary completion
- 2019-03-06
- Enrollment
- 106
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.